Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.0%

13 terminated/withdrawn out of 100 trials

Success Rate

82.7%

-3.8% vs industry average

Late-Stage Pipeline

29%

29 trials in Phase 3/4

Results Transparency

55%

34 of 62 completed trials have results

Key Signals

8 recruiting34 with results13 terminated

Enrollment Performance

Analytics

Phase 2

31(32.6%)

Phase 1

28(29.5%)

Phase 3

27(28.4%)

N/A

6(6.3%)

Phase 4

2(2.1%)

Early Phase 1

1(1.1%)

95Total

Phase 2(31)

Phase 1(28)

Phase 3(27)

N/A(6)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (100)

Showing 20 of 100 trials

NCT03073967Phase 3Completed

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Role: collaborator

NCT07614958Phase 3Recruiting

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

Role: collaborator

NCT07605429Phase 3Not Yet Recruiting

BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.

Role: collaborator

NCT04979806Phase 3Completed

Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Role: collaborator

NCT05291091Phase 2Active Not Recruiting

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Role: collaborator

NCT06066580Phase 2Enrolling By Invitation

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Role: collaborator

NCT06777433Phase 2Active Not Recruiting

Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

Role: collaborator

NCT03624010Phase 2Completed

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Role: collaborator

NCT04329728Phase 1Recruiting

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

Role: collaborator

NCT07197580Phase 3Recruiting

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Role: collaborator

NCT05986851Phase 2Active Not Recruiting

Azeliragon in MGMT Unmethylated Glioblastoma

Role: collaborator

NCT07189871Phase 1Recruiting

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Role: collaborator

NCT07432633Phase 1Recruiting

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Role: collaborator

NCT06564974Recruiting

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

Role: collaborator

NCT05983250Phase 3Recruiting

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Role: collaborator

NCT06160037Not ApplicableCompleted

Influence of Prenatal and Early Childhood Home-Visiting by Nurses on Development of Chronic Disease

Role: collaborator

NCT03340753Phase 1Completed

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

Role: collaborator

NCT04366115Phase 1Not Yet Recruiting

Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS

Role: collaborator

NCT06516510Early Phase 1Terminated

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Role: collaborator

NCT07062471Not ApplicableNot Yet Recruiting

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)

Role: collaborator